Assessment of Drug Therapy-Related Issues in an Outpatient Heart Failure Population and the Potential Impact of Pharmacist-Driven Intervention
| Autor: | Lina Matta, Akshay S. Desai, Lynne W. Stevenson, Craig A. Stevens, Judy W.M. Cheng, Jillian Dempsey, Danielle Carter |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Population Pharmacist Pilot Projects 030204 cardiovascular system & hematology Pharmacists Cohort Studies 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Professional Role Ambulatory care Outpatients medicine Ambulatory Care Humans Pharmacology (medical) Drug Interactions 030212 general & internal medicine Intensive care medicine education Aged Aged 80 and over Heart Failure education.field_of_study business.industry Middle Aged medicine.disease Heart failure Ambulatory Emergency medicine Female Triage business Cohort study Kidney disease |
| Zdroj: | Journal of pharmacy practice. 30(3) |
| ISSN: | 1531-1937 |
| Popis: | Background: The Ambulatory Cardiac Triage, Intervention, and Education (ACTIVE) infusion unit is an outpatient center that aims to provide heart failure (HF) patients with comprehensive multidisciplinary interventions. Objective: To describe the patient population served in ACTIVE and to document the prevalence of comorbidities and drug therapy-related issues (DRIs) in order to define the most effective role of a pharmacist in the unit. Methods: Patients who have been interviewed by a pharmacist in ACTIVE were included. Comprehensive medical and medication profile reviews were performed. Patient comorbidities were documented, and DRIs were classified. Results: Sixty patients were included. Most prevalent cardiac comorbidities included hypertension (73%) and hyperlipidemia (62%). Top 3 noncardiac comorbidities included chronic kidney disease (60%), diabetes (50%), and obesity (35%). The prevalence of DRI was reported as follows: (1) needs additional/alternative therapy (untreated indication [37] or suboptimal therapeutic choice [46]), (2) wrong drug (major drug–drug interaction [90], contraindication [11], or duplicate therapy [1]), (3) suboptimal dosing (17), (4) dose exceeds recommended maximum (9), and (5) adverse drug reaction (93). In 63 (22%) of the DRIs, a pharmacist made recommendations to modify the regimen. Conclusion: The prevalence of DRI is high even among HF patients managed in a subspecialty cardiovascular practice. Pharmacists in this setting play a vital role in more effectively resolving DRI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|